Citation | Ye, XY; Chen, SY; Wu, S; Yoon, DS; Wang, H; Hong, Z; O'Connor, SP; Li, J; Li, JJ; Kennedy, LJ; Walker, SJ; Nayeem, A; Sheriff, S; Camac, DM; Ramamurthy, V; Morin, PE; Zebo, R; Taylor, JR; Morgan, NN; Ponticiello, RP; Harrity, T; Apedo, A; Golla, R; Seethala, R; Wang, M; Harper, TW; Sleczka, BG; He, B; Kirby, M; Leahy, DK; Li, J; Hanson, RL; Guo, Z; Li, YX; DiMarco, JD; Scaringe, R; Maxwell, B; Moulin, F; Barrish, JC; Gordon, DA; Robl, JA Discovery of Clinical Candidate 2-((2S,6S)-2-Phenyl-6-hydroxyadamantan-2-yl)-1-(3'-hydroxyazetidin-1-yl)ethanone [BMS-816336], an Orally Active Novel Selective 11?-Hydroxysteroid Dehydrogenase Type 1 Inhibitor. J Med Chem60:4932-4948 (2017) [PubMed] Article |
---|
SMILES | OC1CN(C1)C(=O)CC1(C2CC3CC1CC(C2)C3O)c1ccccn1 |TLB:12:11:8.13.14:16,7:8:16:10.11.17,19:8:10.12.11:14.15.16,THB:18:17:8.13.14:16,12:13:16:10.11.17,17:11:8:14.15.16,17:15:8:10.12.11,7:8:10.12.11:14.15.16,19:8:16:10.11.17,(42.05,-33.26,;43.19,-34.3,;44.73,-34.22,;44.8,-35.76,;43.27,-35.84,;45.95,-36.79,;45.63,-38.3,;47.42,-36.32,;48.56,-37.35,;49.76,-36.07,;51.08,-36.56,;52.48,-36.21,;51.47,-37.49,;50.06,-36.93,;50.05,-35.34,;51.09,-34.1,;49.75,-34.58,;52.5,-34.68,;53.78,-33.84,;48.55,-38.89,;47.2,-39.64,;47.19,-41.17,;48.51,-41.96,;49.86,-41.19,;49.86,-39.66,)| |